<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097292</url>
  </required_header>
  <id_info>
    <org_study_id>NHStudy (IND)</org_study_id>
    <secondary_id>UC4DK117009</secondary_id>
    <secondary_id>UC4DK106993</secondary_id>
    <nct_id>NCT00097292</nct_id>
  </id_info>
  <brief_title>TrialNet Pathway to Prevention of T1D</brief_title>
  <official_title>TrialNet Pathway to Prevention of T1D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      The accrual of data from the laboratory and from epidemiologic and prevention trials has
      improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus
      (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and
      characterization of the early metabolic abnormalities in T1DM is steadily increasing.
      However, information regarding the natural history of T1DM remains incomplete. The TrialNet
      Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been
      designed to clarify this picture, and in so doing, will contribute to the development and
      implementation of studies aimed at prevention of and early treatment in T1DM.

      Purpose:

      TrialNet is an international network dedicated to the study, prevention, and early treatment
      of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland,
      United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to
      testing new approaches to the prevention of and early intervention for type 1 diabetes.

      The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to
      enhance our understanding of the demographic, immunologic, and metabolic characteristics of
      individuals at risk for developing type 1 diabetes.

      The Natural History Study will screen relatives of people with type 1 diabetes to identify
      those at risk for developing the disease. Relatives of people with type 1 diabetes have about
      a 5% percent chance of being positive for the antibodies associated with diabetes. TrialNet
      will identify adults and children at risk for developing diabetes by testing for the presence
      of these antibodies in the blood. A positive antibody test is an early indication that damage
      to insulin-secreting cells may have begun. If this test is positive, additional testing will
      be offered to determine the likelihood that a person may develop diabetes. Individuals with
      antibodies will be offered the opportunity for further testing to determine their risk of
      developing diabetes over the next 5 years and to receive close monitoring for the development
      of diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:

      The Pathway to Prevention Study is conducted in two parts:

        -  Screening

        -  Monitoring (annual and semi-annual depending on risk)

      In Screening , a simple blood test is done to screen for the presence of diabetes-related
      biochemical autoantibodies (GAD and mIAA). Additional autoantibodies ICA, IA-2A, and ZnT8A
      will also measured in individuals positive for mIAA. ICA, IA-2A, and ZnT8A will be measured
      in individuals positive for GAD. Participants can go to a TrialNet Clinical Center,
      Affiliate, or request a screening kit to have their blood drawn by a local physician or
      laboratory. Participants will be provided with their screening results within 4-6 weeks.

      If autoantibodies are present, participants will be invited to have additional testing to
      determine their average risk of developing diabetes over the next 5 years. Participants that
      are single autoantibody positive will be re-tested annually for the development of multiple
      autoantibodies. Multiple autoantibody positive participants will undergo an eligibility visit
      which will include an Oral Glucose Tolerance Test (OGTT), re-testing for biochemical and
      islet cell autoantibodies if needed, and measurement of HbA1c.

      Multiple autoantibody positive individuals with a normal glucose tolerance and an HbA1c &lt;
      6.0% will be asked to come for follow-up on annual basis; multiple autoantibody positive
      individuals with an abnormal glucose tolerance or an HbA1c â‰¥ 6.0%will be asked to come for
      follow-up visits on semi-annual basis.

      Participants will be monitored for possible progression towards type 1 diabetes and may be
      offered the opportunity to enter into a prevention study such (e.g., Oral Insulin prevention
      study) or an early treatment study if they are diagnosed with type 1 diabetes while
      participating in the Natural History Study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of type 1 diabetes</measure>
    <time_frame>Monitoring is provided once or twice annually depending on risk level</time_frame>
    <description>The primary outcome is the development of diabetes as defined by the American Diabetes Association (ADA) based on glucose testing, or the presence of symptoms and unequivocal hyperglycemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic and Autoantibody Assessments</measure>
    <time_frame>Metabolic and Autoantibody assessments are provided once or twice annually depending on risk level</time_frame>
    <description>Oral Glucose Tolerance Test (OGTT) HbA1c Autoantibodies: ICA, IA-2A, GAD65A, mIAA, ZnT8A</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">75000</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Annual Re-Testing/Annual Metabolic Monitoring</arm_group_label>
    <description>Participants will be monitored annually for risk of type 1 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semi-Annual Metabolic Monitoring</arm_group_label>
    <description>Participants will be monitored every six months for risk of type 1 diabetes</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        First and second/third degree relatives of individuals with type 1 diabetes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals 2.5 to 45 years old who have an immediate family member with type 1
             diabetes (such as a child, parent, or sibling)

          -  Individuals 2.5-20 years old who have an extended family member with type 1 diabetes
             (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)

          -  Individuals 2.5-45 years old without a type 1 diabetes proband, who are known to have
             1 or more islet antibody are eligible for screening if needed to determine eligibility
             for a clinical trial to delay or prevent disease progression.

        Exclusion Criteria:

        To be eligible a person must not:

          -  Have diabetes already

          -  Have a previous history of being treated with insulin or oral diabetes medications.

          -  Currently be using systemic immunosuppressive agents (topical and inhaled agents are
             acceptable)

          -  Have any known serious diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla J Greenbaum, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Benaroya Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TrialNet Central Information Center general info</last_name>
    <phone>1-800-425-8361</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ko</last_name>
      <phone>415-514-3730</phone>
      <email>karen.ko@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trudy Esrey, RD</last_name>
      <phone>650-498-4450</phone>
      <email>tesrey@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Darrell Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Chun</last_name>
      <phone>303-724-5756</phone>
      <email>joyce.chun@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Steck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Feldman</last_name>
      <phone>203-737-2760</phone>
      <email>laurie.feldman@yale.edu</email>
    </contact>
    <contact_backup>
      <phone>(203) 737-2511</phone>
    </contact_backup>
    <investigator>
      <last_name>Kevan Herold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601-0296</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hosford</last_name>
      <phone>352-294-5759</phone>
      <email>jennifer.hosford@peds.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Annie Abraham</last_name>
      <phone>(352) 294-5762</phone>
      <email>abraa@peds.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Desmond A Schatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della Matheson, RN,CDE</last_name>
      <phone>305-243-3781</phone>
      <email>dmatheso@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>David Baidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida Diabetes Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Eyth</last_name>
      <phone>813-974-2793</phone>
      <email>emilyeyth@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Kwapil</last_name>
      <phone>404-727-0637</phone>
      <email>lori.kwapil@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Muir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Gannon</last_name>
      <phone>773-702-3853</phone>
      <email>ggannon@uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Louis Philipson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children, Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Spall</last_name>
      <phone>866-230-8486</phone>
      <email>malnicho@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Linda DeMeglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>58944</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Pappenfus</last_name>
      <phone>612-624-2922</phone>
      <email>papp0086@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Antoinette Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Brenson-Hughes</last_name>
      <phone>816-960-8942</phone>
      <email>dbrensonhughes@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Wayne Moore, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pollak</last_name>
      <phone>212-851-5465</phone>
      <email>sjp2174@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robin S Goland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli DeLallo, RN</last_name>
      <phone>412-692-5210</phone>
      <email>kelli.delallo@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothy Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faith Brendle, RN</last_name>
      <phone>615-936-8638</phone>
      <email>faith.brendle@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>William Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Boyles</last_name>
      <phone>214-648-4717</phone>
      <email>lauren.boyles@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Raskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Pena</last_name>
      <phone>832-822-3380</phone>
      <email>sypena@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Maria Redondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101-2795</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Snavely</last_name>
      <phone>206-342-6590</phone>
      <email>jsnavely@benaroyaresearch.org</email>
    </contact>
    <investigator>
      <last_name>Carla Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter and Eliza Hall Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicity Healy</last_name>
      <phone>61-3-9342 7063</phone>
      <email>felicity.healy@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Peter C Colman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G-1x8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jo Ricci</last_name>
      <phone>(416) 813-7654</phone>
      <phone_ext>202634</phone_ext>
      <email>maryjo.ricci@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Wherrett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Turku</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Adamsson</last_name>
      <phone>+358405644674</phone>
      <email>annika.adamsson@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Jorma Toppari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vita-Salute San Raffaele University</name>
      <address>
        <city>Milan</city>
        <zip>+39-02-2643 2818</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Grogan, RN</last_name>
      <phone>+39-02-2643 2818</phone>
      <email>grogan.pauline@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Emanuele Bossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB UK</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harriet Castleden</last_name>
      <phone>44 117 323 8737</phone>
      <email>harriet.castleden@bristol.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Polly Bingley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetestrialnet.org</url>
    <description>TrialNet Study Group</description>
  </link>
  <link>
    <url>https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/special-diabetes-program-clinical-trials-recruiting-patients-families</url>
    <description>Type 1 Diabetes Clinical Trials</description>
  </link>
  <link>
    <url>http://www.diabetes.org</url>
    <description>American Diabetes Association</description>
  </link>
  <link>
    <url>http://www.jdrf.org</url>
    <description>Juvenile Diabetes Research Foundation International</description>
  </link>
  <reference>
    <citation>Diabetes Prevention Trial--Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002 May 30;346(22):1685-91.</citation>
    <PMID>12037147</PMID>
  </reference>
  <reference>
    <citation>Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004 Mar 20;363(9413):925-31.</citation>
    <PMID>15043959</PMID>
  </reference>
  <reference>
    <citation>Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001 Jul 21;358(9277):221-9. Review. Erratum in: Lancet. 2001 Sep 1;358(9283):766.</citation>
    <PMID>11476858</PMID>
  </reference>
  <reference>
    <citation>Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996 Jul;45(7):926-33.</citation>
    <PMID>8666144</PMID>
  </reference>
  <reference>
    <citation>Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes. 1994 Nov;43(11):1304-10.</citation>
    <PMID>7926304</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 19, 2004</study_first_submitted>
  <study_first_submitted_qc>November 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2004</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>&quot;at risk&quot; for developing type 1 diabetes</keyword>
  <keyword>T1DM</keyword>
  <keyword>T1D</keyword>
  <keyword>juvenile diabetes</keyword>
  <keyword>Type 1 Diabetes TrialNet</keyword>
  <keyword>TrialNet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

